复方甘草酸苷联合苦参素治疗慢性肝炎患者对血清肝纤维化指标的影响

Efficacy of compound glycyrrhizin and matrine in the treatment of patients with chronic hepatitis B and C

目的观察复方甘草酸苷联合苦参素治疗慢性肝炎患者对血清肝纤维化指标的影响。方法将56例慢性乙型肝炎或慢性丙型肝炎患者随机分成对照组与治疗组,每组28例,分别应用苦参素或复方甘草酸苷联合苦参素治疗,疗程12周。结果在治疗结束后,联合组患者ALT为(34.9±18.4)U/L,HA为(129.4±98.2)ng/ml,LN为(130.7±71.2)ng/ml,PⅢNP为(25.3±14.8)ng/ml,CⅣ为(100.5±34.2)ng/ml,均显著低于对照组[分别为(ALT58.4±37.7)U/L、(182.2±93.3)ng/ml、(176.6±91.6)ng/ml、(35.4±21.4)ng/ml和(128.4±51.9)ng/ml,P<0.05]。结论复方甘草酸苷联合苦参素能明显降低慢性肝炎患者血清肝纤维化指标。